Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

This study tests a new PET scan imaging agent that targets alpha-synuclein — a protein that builds up abnormally in multiple system atrophy (MSA), a rare and serious brain condition that affects movement, balance, and automatic body functions like blood pressure and bladder control. The goal is to improve early and accurate diagnosis. **You may be eligible if...** - You are older than 35 years of age (any gender) - You have been clinically diagnosed with MSA based on the 2022 Movement Disorder Society criteria - You have been tested for genetic conditions that mimic MSA and results came back negative - You are willing to volunteer and sign informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have contraindications to MRI (like metal implants or severe claustrophobia) - You have another serious neurological condition that could confuse the diagnosis Talk to your doctor to see if this trial is right for you.